[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557993":3},{"organization":4,"armGroups":7,"interventions":23,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":239,"collaborators":29,"id":241,"slug":242,"hasResults":243,"nctId":244,"briefTitle":245,"officialTitle":246,"acronym":29,"eligibilityCriteria":247,"healthyVolunteers":243,"sex":248,"minAge":249,"maxAge":29,"enrollmentInfo":250,"targetDuration":29,"studyType":253,"phases":254,"briefSummary":256,"conditions":257,"keywords":29,"overallStatus":50,"whyStopped":29,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":268,"completionDateStruct":270,"leadSponsor":272,"locationsCount":273},{"fullName":5,"class":6},"Exelixis","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"XB010 Single-Agent Dose Escalation Cohorts","EXPERIMENTAL","XB010 will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects",[13],"Drug: XB010",{"label":15,"type":10,"description":16,"interventionNames":17},"XB010 + Pembrolizumab Dose Escalation Cohorts","XB010+Pembrolizumab will be administered at escalating dose levels every 3 weeks in cohorts of 3-12 subjects",[13,18],"Drug: Pembrolizumab",{"label":20,"type":10,"description":21,"interventionNames":22},"XB010 Single-Agent Dose Expansion Cohorts","XB010 will be administered at the recommended dose for expansion (RDE) every 3 weeks in the following tumor-specific cohorts: non-small cell lung cancer (NSCLC), hormone-receptor-positive breast cancer (HR+BC), head and neck squamous cell cancer (HNSCC), esophageal squamous cell cancer (ESCC), endometrial cancer (EC) and triple-negative breast cancer (TNBC)",[13],[24,30],{"type":25,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","XB010","IV administration of XB010",[15,9,20],null,{"type":25,"name":31,"description":32,"armGroupLabels":33,"otherNames":29},"Pembrolizumab","IV administration of Pembrolizumab",[15],[35],{"name":36,"affiliation":5,"role":37},"Study Director","STUDY_DIRECTOR",[39,44],{"name":40,"role":41,"phone":42,"phoneExt":29,"email":43},"Exelixis Clinical Trials","CONTACT","1-888-EXELIXIS (888-393-5494)","druginfo@exelixis.com",{"name":45,"role":41,"phone":46,"phoneExt":29,"email":29},"Backup or International","650-837-7400",[48,62,71,81,91,101,111,121,131,141,151,161,171,180,189,199,204,215,224,230],{"facility":49,"status":50,"city":51,"state":52,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":29},"City of Hope Orange County Lennar Foundation Cancer Center","RECRUITING","Irvine","California","91010","United States","US",{"type":57,"coordinates":58},"Point",[59,60],-117.82311,33.66946,{"lat":60,"lon":59},{"facility":63,"status":50,"city":64,"state":52,"zip":65,"country":54,"countryCode":55,"cosmosGeoPoint":66,"geoPoint":70,"contacts":29},"UCLA Department of Medicine - Hematology\u002FOncology","Los Angeles","90095",{"type":57,"coordinates":67},[68,69],-118.24368,34.05223,{"lat":69,"lon":68},{"facility":72,"status":50,"city":73,"state":74,"zip":75,"country":54,"countryCode":55,"cosmosGeoPoint":76,"geoPoint":80,"contacts":29},"Georgetown University Medical Center","Washington D.C.","District of Columbia","20007",{"type":57,"coordinates":77},[78,79],-77.03637,38.89511,{"lat":79,"lon":78},{"facility":82,"status":50,"city":83,"state":84,"zip":85,"country":54,"countryCode":55,"cosmosGeoPoint":86,"geoPoint":90,"contacts":29},"Sarah Cannon Research Institute at Florida Cancer Specialists","Orlando","Florida","32827",{"type":57,"coordinates":87},[88,89],-81.37924,28.53834,{"lat":89,"lon":88},{"facility":92,"status":50,"city":93,"state":94,"zip":95,"country":54,"countryCode":55,"cosmosGeoPoint":96,"geoPoint":100,"contacts":29},"Winship Cancer Institute","Atlanta","Georgia","30322",{"type":57,"coordinates":97},[98,99],-84.38798,33.749,{"lat":99,"lon":98},{"facility":102,"status":50,"city":103,"state":104,"zip":105,"country":54,"countryCode":55,"cosmosGeoPoint":106,"geoPoint":110,"contacts":29},"University of Chicago Medical Center","Chicago","Illinois","60637",{"type":57,"coordinates":107},[108,109],-87.65005,41.85003,{"lat":109,"lon":108},{"facility":112,"status":50,"city":113,"state":114,"zip":115,"country":54,"countryCode":55,"cosmosGeoPoint":116,"geoPoint":120,"contacts":29},"Siteman Cancer Center","St Louis","Missouri","63110",{"type":57,"coordinates":117},[118,119],-90.19789,38.62727,{"lat":119,"lon":118},{"facility":122,"status":50,"city":123,"state":124,"zip":125,"country":54,"countryCode":55,"cosmosGeoPoint":126,"geoPoint":130,"contacts":29},"Montefiore Medical Center - Montefiore Medical Park","The Bronx","New York","10461",{"type":57,"coordinates":127},[128,129],-73.86641,40.84985,{"lat":129,"lon":128},{"facility":132,"status":50,"city":133,"state":134,"zip":135,"country":54,"countryCode":55,"cosmosGeoPoint":136,"geoPoint":140,"contacts":29},"Carolina BioOncology Institute","Huntersville","North Carolina","28078",{"type":57,"coordinates":137},[138,139],-80.84285,35.41069,{"lat":139,"lon":138},{"facility":142,"status":50,"city":143,"state":144,"zip":145,"country":54,"countryCode":55,"cosmosGeoPoint":146,"geoPoint":150,"contacts":29},"Stephenson Cancer Center","Oklahoma City","Oklahoma","73104",{"type":57,"coordinates":147},[148,149],-97.51643,35.46756,{"lat":149,"lon":148},{"facility":152,"status":50,"city":153,"state":154,"zip":155,"country":54,"countryCode":55,"cosmosGeoPoint":156,"geoPoint":160,"contacts":29},"SCRI Oncology Partners","Nashville","Tennessee","37203",{"type":57,"coordinates":157},[158,159],-86.78444,36.16589,{"lat":159,"lon":158},{"facility":162,"status":50,"city":163,"state":164,"zip":165,"country":54,"countryCode":55,"cosmosGeoPoint":166,"geoPoint":170,"contacts":29},"NEXT Austin","Austin","Texas","78758",{"type":57,"coordinates":167},[168,169],-97.74306,30.26715,{"lat":169,"lon":168},{"facility":172,"status":50,"city":173,"state":164,"zip":174,"country":54,"countryCode":55,"cosmosGeoPoint":175,"geoPoint":179,"contacts":29},"Baylor University Medical Center","Dallas","75246",{"type":57,"coordinates":176},[177,178],-96.80667,32.78306,{"lat":178,"lon":177},{"facility":181,"status":50,"city":182,"state":164,"zip":183,"country":54,"countryCode":55,"cosmosGeoPoint":184,"geoPoint":188,"contacts":29},"University of Texas MD Anderson Cancer Center","Houston","77030",{"type":57,"coordinates":185},[186,187],-95.36327,29.76328,{"lat":187,"lon":186},{"facility":190,"status":50,"city":191,"state":192,"zip":193,"country":54,"countryCode":55,"cosmosGeoPoint":194,"geoPoint":198,"contacts":29},"Inova Schar Cancer","Fairfax","Virginia","22031",{"type":57,"coordinates":195},[196,197],-77.30637,38.84622,{"lat":197,"lon":196},{"facility":200,"status":50,"city":191,"state":192,"zip":193,"country":54,"countryCode":55,"cosmosGeoPoint":201,"geoPoint":203,"contacts":29},"NEXT Virginia",{"type":57,"coordinates":202},[196,197],{"lat":197,"lon":196},{"facility":205,"status":50,"city":206,"state":29,"zip":207,"country":208,"countryCode":209,"cosmosGeoPoint":210,"geoPoint":214,"contacts":29},"University Hospitals of Leicester NHS Trust","Leicester","LE1 5WW","United Kingdom","UK",{"type":57,"coordinates":211},[212,213],-1.13169,52.6386,{"lat":213,"lon":212},{"facility":216,"status":50,"city":217,"state":29,"zip":218,"country":208,"countryCode":209,"cosmosGeoPoint":219,"geoPoint":223,"contacts":29},"Sarah Cannon Research Institute London","London","W1G 6AD",{"type":57,"coordinates":220},[221,222],-0.12574,51.50853,{"lat":222,"lon":221},{"facility":225,"status":50,"city":217,"state":29,"zip":226,"country":208,"countryCode":209,"cosmosGeoPoint":227,"geoPoint":229,"contacts":29},"University College London Hospitals NHS Foundation Trust","W1T 7HA",{"type":57,"coordinates":228},[221,222],{"lat":222,"lon":221},{"facility":231,"status":50,"city":232,"state":29,"zip":233,"country":208,"countryCode":209,"cosmosGeoPoint":234,"geoPoint":238,"contacts":29},"The Christie NHS Foundation Trust","Manchester","M20 4BX",{"type":57,"coordinates":235},[236,237],-2.23743,53.48095,{"lat":237,"lon":236},{"type":240,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100557993","phase-1-study-of-xb010-in-subjects-with-solid-tumors-100557993",false,"NCT06545331","Study of XB010 in Subjects With Solid Tumors","A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors","* Age 18 years or older on the day of consent.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* Adequate organ and marrow function.\n* Cytologically or histologically and radiologically confirmed solid tumor that is inoperable, locally advanced, metastatic, or recurrent.\n\n  * The Cohort Expansion stage will enroll subjects with multiple tumor types (non-small cell lung cancer, hormone-receptor-positive breast cancer, head and neck cancer, esophageal squamous cell, triple-negative breast cancer).\n* Capable of understanding and complying with the protocol requirements and must have signed the informed consent document.","ALL","18 Years",{"count":251,"type":252},396,"ESTIMATED","INTERVENTIONAL",[255],"PHASE1","This is a FIH study is to evaluate the safety, tolerability, PK, immunogenicity, and preliminary antitumor activity of XB010 as a single agent and in combination with pembrolizumab in subjects with locally advanced or metastatic solid tumors for whom alternative therapies do not exist or available therapies are intolerable or no longer effective.",[258,259,260,261,262,263],"Locally Advanced or Metastatic Solid Tumors","Esophageal Squamous Cell Cancer","Head and Neck Squamous Cell Cancer","NSCLC (Non-small Cell Lung Cancer)","Hormone-receptor-positive Breast Cancer","Triple Negative Breast Cancer (TNBC)","2026-06-17",{"date":266,"type":267},"2026-06-22","ACTUAL",{"date":269,"type":267},"2024-08-06",{"date":271,"type":252},"2027-10-20",{"name":5,"class":6},20]